Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

CorMedix (CRMD) Worth Watching: Stock Soars 19.9%

CorMedix, Inc. CRMD was a big mover last session with its shares surging almost 20% on the day. The upside came on the company’s announcement that Dr. Christoph Wanner, Professor of Medicine and Director of Nephrology at the University of Wurzburg will present post-Market clinical utility data from the Neutrolin Usage Monitoring Program on May 23, 2016, at the at the 53rd Joint Congress of the European Renal Association - European Dialysis and Transplant Association. This development led to far more shares changing hands yesterday than in a normal session. The move breaks the recent trend of the company as the stock is now trading above the past one month’s volatile price range of $2.28 to $3.27.

This biopharmaceutical company has seen 3 positive estimate revisions in the last 30 days. The Zacks Consensus Estimate has also moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.

CorMedix currently has a Zacks Rank #1 (Strong Buy) and its Earnings ESP is 0.00%.

Investors interested in the med-biomed/gene industry may also consider Gilead Sciences Inc. GILD that carries the same Zacks Rank as CorMedix.

Is CRMD going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GILEAD SCIENCES (GILD): Free Stock Analysis Report
 
CORMEDIX INC (CRMD): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research